Novo Nordisk A/S’s Return on Equity at a glance
Novo Nordisk A/S reports return on equity of 70.4% for Dec 2024. The prior period recorded 78.5% (Dec 2023). Year over year the metric moved −8.1 pts (−10.4%). The rolling three-period average stands at 71.8%. Data last refreshed Dec 7, 2025, 2:48 AM.
Latest reading
70.4% · Dec 2024
YoY movement
−8.1 pts (−10.4%)
Rolling average
71.8%
Current Return on Equity
70.4%
−8.1 pts
−10.4%
Rolling average
71.8%
Latest Value
70.4%
Dec 2024
YoY Change
−8.1 pts
Absolute
YoY Change %
−10.4%
Rate of change
3-Period Avg
71.8%
Smoothed
Narrative signal
Novo Nordisk A/S’s return on equity stands at 70.4% for Dec 2024. Year-over-year, the metric shifted by −8.1 pts, translating into a −10.4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How return on equity shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports return on equity of 70.4%. Monitor ROE trends to assess management efficiency and the impact of leverage on profitability.
ROE as a performance score
High and stable ROE signals strong business models and effective capital deployment.
Leverage considerations
Rising debt can boost ROE. Pair the metric with leverage ratios to avoid overstating performance.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s return on equity profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current return on equity?
As of Dec 2024, Novo Nordisk A/S reports return on equity of 70.4%. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's return on equity trending year over year?
Year-over-year, the figure shifts by −8.1 pts (−10.4%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does return on equity matter for Novo Nordisk A/S?
Return on equity measures how effectively a company converts shareholder capital into net income. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's return on equity above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 71.8%. Comparing the latest reading of 70.4% to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's return on equity refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:48 AM and updates automatically every 24 hours, keeping your valuation inputs current.